A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 1, 2005, Pages 117-125

  Jablkowski, M ^a   Bocian, A ^b   Bialkowska, J ^a   Bartkowiak, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Holycross Cancer Center   (Poland)

Author keywords

Hepatocellular carcinoma; Liver cirrhosis; MDM2 amplification; P53 mutations; P53 MDM2 immunoreactivity

Indexed keywords

AFLATOXIN; GENE PRODUCT; PROTEIN MDM2; PROTEIN P53;

ALLELISM; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; GENE AMPLIFICATION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENETIC STABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR GROWTH;

CARCINOMA, HEPATOCELLULAR; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MUTATION; NUCLEAR PROTEINS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 18544372089     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Chen P.J., Chen D.S.: Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin. Liver Dis. 19: 253-262, 1999.
2. Colombo M.: Hepatitis C virus and hepatocellular carcinoma. Semin. Liver Dis. 19: 263-270, 1999.
3. Levy L., Renard C.A., Wei Y., Buendia M.A.: Genetic alternations and oncogenic pathways in hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 936: 21-36, 2002.
4. Chen X., Cheung S.T., So S., Fan S.T., Barry C., Higgins J., Lai K.M., Ji J., Dudoit S., Ng I.O., Van De Rijn M., Botstein D., Brown P.O.: Gene expression patterns in human liver cancer. Mol. Biol. Cell 13: 1929-1939, 2002.
5. Bergsland E.K.: Molecular mechanisms underlying the development of hepatocellular carcinoma. Semin. Oncol. 28: 521-531, 2001.
6. Edamoto Y., Hara A., Biernat W., Terracciano L., Cathomas G., Riehle K., Matsuda M., Fujii H., Scoazec J.Y., Ohgaki H.: Alternation of RB1, p53 and Wtn pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcohol liver cirrhosis. Int. J. Cancer 106: 334-341, 2003.
7. Endo K., Ueda T., Ohta T., Terada T.: Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 20: 209-, 2000.
8. Guimaraes D.P., Hainaut P.: TP53: a key gene in human cancer. Biochimie 84: 83-93, 2002.
9. Xu H., el-Gewely M.R.: P53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol. Annu. Rev. 7: 131-164, 2001.
10. Landers J.E., Haines D.S., Strauss J.F., George D.L.: Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9: 2745-2750, 1994.
11. Chen C.Y., Oliner J.D., Zhan Q., Fornace A.J., Vogelsttein B., Kastan M.B.: Interactions between p53 and MDM2 in mammalian cell cycle check point pathway. Proc. Natl. Acad. Sci. USA 91: 2684-2688, 1994.
12. Shmueli A., Oren M.: Regulation of p53 by Mdm2. Fate is in the numbers. Mol. Cell. 13: 4-5, 2004.
13. Lahav G., Rosenfeld N., Sigal A., Geva-Zatorsky N., Levine A.J., Elowitz M.B., Alon U.: Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat. Genet. Jan. 18, 2004.
14. Reid A.H., Tsai M.M., Venzon D.J., Wright C.F., Lack E.E., O'Leary T.J.: MDM2 amplification, P53 mutation,and accumulation of the P53 gene product in malignant fibrous histiocytoma. Diag. Mol. Pathol. 5: 65-73, 1996.
15. Dei Tos A.P., Doglioni C., Piccinin S., Maestro R., Mentzel T.H., Barbareschi M., Boiocchi M., Fletcher C.D.M.: Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J. Pathol. 181: 8-13, 1997.
16. Zhu Y.M., Foroni L., McQuaker I.G., Papaioannou M., Haynes A., Russell H.H.: Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia. Br. J. Cancer 79: 1151-1157, 1999.
17. Katiyar S., Dash B.C., Thakur V., Guptan R.C., Sarin S.K., Das B.C.: P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer 88: 1565-1573, 2000.
18. Taubert H., Wurl P., Meyer A., Berger D., Thamm B., Neumann K., Hinze R., Schmidt H., Rath F-W.: Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Identification of seven new mutations for soft tissue sarcomas. Cancer 76: 1187-1196, 1995.
19. Capoulade C., Bressac-de Paillerets B., Lefrere I., Ronsin M., Feunteun J., Tursz T., Wiels J.: Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 16: 1603-1610, 1998.
20. Lonardo F., Ueda T., Huvos A.G., Healey J., Ladanyi M.: P53 and MDM2 alterations in osteosarcomas. Correlation with clinicopathologic features and proliferative rate. Cancer 79: 1541-1547, 1997.
21. Qiu S.J., Ye S.L., Wu Z.Q., Tang Z.Y., Liu Y.K.: The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J. Cancer Clin. Oncol. 124: 253-258, 1998.
22. Pilotti S., Delia Tore G., Lavarino C., Di Palma S., Sozzi G., Minoletti F., Rao S., Pasquini G., Azzarelli A., Rilke F., Pierotti M.A.: Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J. Pathol. 181: 14-24, 1997.
23. Preudhomme C., Quesnel B., Vachee A., Lepelley P., Collyn-D'Hooghe M., Wattel E., Fenaux P.: Absence of amplification of mdm2 gene, as a regulator of p53 function, in myelodysplastic syndromes. Leukemia 7: 1291-1293, 1993.
24. Sambrook J., Fritsch E.F., Maniatis T.: Molecular cloning. A laboratory manual, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989.
25. Orita M., Suzuki Y., Sekyia T., Hayashi K.: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879, 1989.
26. Soto D., Sukumar S.: Improved detection of mutation in the p53 gene in human tumors as single strand conformation polymorphism and double strand heteroduplex DNA. PCR Meth. Appl. 2: 96-98, 1992.
27. Hunter S.B., Abbott K., Varma V.A., Olson J.J., Barnett D.W., James C.D.: Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J. Neuropathol. Exp. Neurol. 54: 57-64, 1995.
28. Peng C.Y., Chen T.C., Hung S.P., Chen M.F., Yeh C.T., Tsai S.L., Chu C.M., Liaw Y.F.: Genetic alternations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma. Anticancer Res. 22: 1265-1271, 2002.
29. Hartmann A., Blaszyk H., McGovern R.M., Schroeder J.J., Cunningham J., De Vries E.M.G., Kovach J.S., Sommer S.S.: P53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 10: 681-688, 1995.
30. Cesarman E., Inghirami G., Chadburn A., Knowles D. M.: High level of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am. J. Pathol. 143: 845-856, 1993.
31. Qin L.X., Tang Z.Y., Ma Z.C., Wu Z.Q., Zhou X.D., Ye Q.H., Ji Y., Huang I., Jia H.L., Sun H.C., Wang L.: P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J. Gastroenterol. 8: 459-463, 2002.
32. Kawamata N., Miller C., Levy V., Shintaku I.P., Koeffler H.P., Said J.W.: mdm-2 oncogene expression in non-hodgkin's lymphomas. Diag. Mol. Phatol. 5: 33-38, 1996.
33. Nakayama T., Toguchida J., Wadayama B., Kaone H., Kotoura Y., Sasaki M. S.: MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose tissue tumors. Int. J. Cancer 64: 342-346, 1996.
34. Miller C.W., Aslo A., Won A., Tan M., Lampkin B., Koeffler P.: Alterations of the p53, Rb, and MDM2 gene in osteosarcomas. J. Cancer Clin. Oncol. 122: 559-565, 1996.
35. Matsumoto R., Tada M., Nozaki M., Zhang C-L., Sawamura Y., Abe H.: Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res. 58: 609-613, 1998.
36. Haupt Y., Maya R., Kazaz A., Oren M.: MDM2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
37. Berberich S., Cole M.: The mdm-2 oncogene is translocated and overexpressed in a murine plasmocytoma cell line expressing wild-type p53. Oncogene 9: 1469-1472, 1994.
38. Maestro R., Gloghini A., Dogliono C.: MDM2 overexpression does not account for stabilization of wild type p53 protein. Blood 11: 3329-3334, 1995.
39. Peller S., Yona R., Kopilova Y, Prokocimer M., Goldfinger N., Uysal A., Karabulut H.G., Tukun A., Bokesoy I., Tuncman G., Rotter V.: Molecular alternations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia. Gen. Chrom. Cancer 21: 2-7, 1998.
40. Matsumoto R., Tada M., Nozaki M., Zhang C-L., Sawamura Y., Abe H.: Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res. 58: 609-613, 1998.
41. Guinn B-A., Mills K.: p53 mutation, methylation and genomic instability in the progression of chronic myeloid leukaemia. Leuk. Lymph. 26: 211-226, 1997.
42. Martin K., Trouche D., Hagemeier C., Sorensen T.S., La Thangue N.B., Kouzarides T.: Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694, 1995.
43. Alarcon-Vargas D., Ronai Z.: p53-Mdm2 - the affair that never ends. Carcinogenesis 23: 541-547, 2002.
44. Prives C.: Signaling to p53: breaking the MDM2-p53 circuit. Cell 95: 5-8, 1998.